Non-compartmental analysis (NCA) is a model-independent approach to analyzing pharmacokinetic data that does not assume a specific compartmental structure. Unlike compartmental modeling, which requires fitting data to a predefined mathematical model, NCA derives pharmacokinetic parameters directly from the concentration-time curve using numerical integration and statistical moment theory. This approach is widely preferred by regulatory agencies for bioavailability and bioequivalence studies because it makes fewer assumptions and provides robust, reproducible parameter estimates.
Area Under the Curve Calculation
The fundamental parameter in NCA is the area under the concentration-time curve (AUC) , which represents total systemic drug exposure over time. AUC is calculated using the linear trapezoidal rule, where the area between consecutive concentration measurements is approximated as a trapezoid. For the interval from time t1 to t2, the area equals the average of the concentrations at the two time points multiplied by the time difference.
The total AUC from time zero to infinity (AUC0-inf) is calculated as the sum of AUC from time zero to the last measurable concentration (AUC0-last) plus the extrapolated area from the last time point to infinity. The extrapolated portion is calculated as the last measured concentration divided by the terminal elimination rate constant (lambda z). The contribution of the extrapolated area should ideally be less than 20% of the total AUC to ensure reliable parameter estimation.
Area Under the First Moment Curve
The area under the first moment curve (AUMC) is the area under the product of concentration multiplied by time versus time. AUMC is calculated using the same trapezoidal rule but applied to C multiplied by t rather than C alone. AUMC requires extrapolation from the last time point to infinity: the extrapolated portion is calculated as t_last multiplied by C_last divided by lambda z plus C_last divided by lambda z squared.
AUMC is used together with AUC to calculate the mean residence time (MRT) : MRT equals AUMC divided by AUC. MRT represents the average time that drug molecules spend in the body before being irreversibly eliminated. For an intravenous bolus, MRT equals the sum of the mean absorption time and the mean transit time through the body.
Clearance and Volume of Distribution
In NCA, clearance (CL) is calculated as dose divided by AUC for an intravenous administration. This calculation follows directly from the definition of clearance and does not depend on any compartmental assumptions. For extravascular administration, clearance equals dose multiplied by bioavailability divided by AUC.
The volume of distribution at steady state (Vss) is calculated as clearance multiplied by MRT. This relationship holds because Vss equals CL multiplied by MRT for an intravenous bolus administration. For extravascular routes, Vss is calculated as CL multiplied by MRT multiplied by the fraction of dose absorbed relative to intravenous administration.
The terminal elimination half-life is calculated from the terminal elimination rate constant as t½ equals 0.693 divided by lambda z. The terminal rate constant lambda z is estimated by linear regression of the natural logarithm of concentration versus time during the terminal phase. Careful selection of the points included in the regression is important: too few points reduces precision, while including points from the distribution phase biases the estimate.
Advantages over Compartmental Models
NCA offers several advantages over compartmental modeling. It does not require assumptions about the number of compartments or the structure of the model, avoiding the risk of model misspecification. The calculations are standardized and reproducible, providing consistent results across different analysts and software packages. NCA is particularly well suited for studies with relatively sparse sampling schedules, where compartmental models may not be identifiable.
The primary limitation of NCA is that it does not provide mechanistic insight into the underlying pharmacokinetic processes. NCA describes what happened but does not explain why. It also does not readily predict concentration-time profiles under alternative dosing regimens, which requires a compartmental model or physiologically based modeling approach. NCA treats each dose administration independently and does not incorporate prior knowledge about the drug’s pharmacokinetics.
Statistical Moment Theory
NCA is grounded in statistical moment theory, which treats the concentration-time curve as a statistical distribution of drug molecule residence times. The zero-order moment is AUC, representing total exposure. The first-order moment is MRT, representing the average residence time. Higher moments exist but are rarely used in practice.
The major advantage of the moment approach is that it separates the analysis from any specific model structure. The moments are calculated directly from the observed data using numerical integration, and the derived parameters (CL, Vss, MRT) are model-independent provided the data adequately characterize the entire concentration-time profile. Regulatory agencies worldwide accept NCA as the standard method for analyzing pharmacokinetic data in clinical trials, and it remains the primary analytical approach for bioequivalence assessment and new drug applications.
